Immune cell boost shows promise for Tough-to-Treat leukemia
NCT ID NCT03068819
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 31 times
Summary
This study tested a new treatment for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. The treatment used specially trained immune cells (CIML NK cells) from the original donor, combined with standard donor lymphocyte infusions, to help the body fight the cancer. The goal was to see if this approach was safe and could lead to remission. The trial included 62 participants and focused on feasibility, safety, and leukemia-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.